Investing.com - Financial Markets Worldwide

Nigeria to take delivery of 3.92 mln doses of COVID-19 vaccine on Tuesday

Published 28/02/2021, 19:40
© Reuters

ABUJA, Feb 28 (Reuters) - Nigeria expects to take delivery
of 3.92 million doses of the COVID-19 vaccine on Tuesday, the
third West African country to benefit from the COVAX facility
after Ghana and Ivory Coast, the government's coronavirus task
force said on Sunday.
Nigeria, Africa's most populous country with some 200
million people, has reported fewer than 1,900 COVID-19 deaths so
far, much better than had been widely predicted early in the
pandemic.
Last week, Nigerian drug regulator approved the
Astrazeneca/Oxford COVID-19 vaccine use in Nigeria. The dispatch is part of an overall 16 million doses planned
to be delivered to Nigeria in batches over the next months by
the COVAX facility, the task force said in a tweet.
The COVAX facility for poor and middle-income countries is
co-led by Gavi, the vaccine alliance, and the World Health
Organization, with UNICEF as an implementing partner.
Nigeria plans to inoculate 40% of the population this year
and 30% more in 2022. The country expects to receive vaccine
donations that will cover one-fifth of its population and then
procure an additional 50% of its requirement to achieve herd
immunity, the budget head has said.
Finance Minister Zainab Ahmed said Nigeria will draw up a
supplementary budget in March to cover the cost of COVID-19
vaccinations, for which no provision was made in the 2021
finance bill adopted in December.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.